pemetrexed / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

126 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pemetrexed / Generic mfg.
CTR20201857: Phase III clinical study of ametinib mesylate or placebo combined with chemotherapy as perioperative treatment for non-small cell lung cancer

Not yet recruiting
3
350
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx, Pemfexy (pemetrexed) - Eagle Pharma, cisplatin - Generic mfg., carboplatin - Generic mfg.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd./Shanghai Hansoh Biomedical Technology Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
WJOG11218L, jRCT2080224500: A multicentre, open-label, randomized Phase III Study of Atezolizumab with Platinum-Pemetrexed with or without Bevacizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer ( Investigator-Initiated Clinical Trial)

Completed
3
400
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche, carboplatin - Generic mfg., pemetrexed - Generic mfg.
Kyushu University Hospital, Chugai Pharmaceutical Co., Ltd
Non-Small-Cell Lung Cancer;Oncology
 
 
ZEAL, NCT00418886 / 2006-003695-35: Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Checkmark Data
Feb 2011 - Feb 2011: Data
Completed
3
698
Europe, US, RoW
Vandetanib, ZACTIMA™, ZD6474, SAR390530, Pemetrexed, Pemetrexed disodium, Alimta®
Genzyme, a Sanofi Company
Non Small Cell Lung Cancer, Lung Cancer
09/08
02/23
NCT01828112 / 2012-005637-36: LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Completed
3
231
Europe, Canada, Japan, US, RoW
Ceritinib, pemetrexed, docetaxel
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
01/16
11/23
2016-001063-36: Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer Etude randomisée de phase III testant le nivolumab versus une chimiothérapie adaptée dans le traitement de première ligne du CBNPC chez des patients PS 2 ou de plus de 70 ans

Ongoing
3
242
Europe
nivolumab, carboplatin, pemetrexed, paclitaxel, gemcitabine, vinorelbine, Solution for infusion, Solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Capsule, soft, OPDIVO
CHU Rennes, Bristol-Myers Squibb
Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Advanced non small cell lung cancer Cancer Bronchique Non à Petites Cellules avancé, Diseases [C] - Cancer [C04]
 
 
ASCEND-4, NCT01828099 / 2013-000319-26: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Checkmark ASCEND-4 trial in ALK+ NSCLC
Apr 2017 - Apr 2017: ASCEND-4 trial in ALK+ NSCLC
Checkmark ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Sep 2016 - Sep 2016: ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Completed
3
376
Europe, Japan, RoW
Ceritinib, LDK378, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/16
01/24
KEYNOTE-189, NCT02578680 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/)

Checkmark From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Dec 2019 - Dec 2019: From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Checkmark Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Sep 2019 - Sep 2019: Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Checkmark Updated data in combination with Alimta for metastatic nonsquamous 1L NSCLC
More
Completed
3
616
NA
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
11/17
06/23
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
Checkmark OS data from MYSTIC trial in 1L NSCLC
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/24
KEYNOTE-189 Japan Extension study, NCT03950674 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Checkmark Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Checkmark Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Sep 2022 - Sep 2022: Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Checkmark From KEYNOTE-189 in 2L NSCLC
More
Completed
3
40
Japan
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
05/19
06/23
2018-004720-11: Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Ongoing
3
792
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), Pembrolizumab, Olaparib, ALIMTA, Pemetrexed, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, Powder for concentrate for solution for infusion, KEYTRUDA® (pembrolizumab, MK-3475), ALIMTA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Stage IV lung cancer condition, Stage IV lung cancer condition, Diseases [C] - Cancer [C04]
 
 
CheckMate 9LA, NCT03215706 / 2017-001195-35: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Checkmark Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
More
Active, not recruiting
3
719
Europe, Canada, Japan, US, RoW
Ipilimumab, Yervoy, BMS734016, Nivolumab, Opdivo, BMS936558, Carboplatin, Paclitaxel, Taxol, Pemetrexed, Alimta, Cisplatin, Platinol
Bristol-Myers Squibb
Non-Small Cell Lung Cancer
08/19
01/26
ATALANTE 1, NCT02654587 / 2015-003183-36: OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Terminated
3
219
Europe, US, RoW
OSE2101, TEDOPI, EP-2101, EP2101, IDM-2101, Docetaxel, Taxotere, Pemetrexed, Alimta
OSE Immunotherapeutics, OSE Immunotherapeutics, OSE Pharma
Non Small Cell Lung Cancer
01/21
01/21
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
2019-002463-10: A study of BLU-667 in patients with lung cancer

Not yet recruiting
3
250
Europe
Pralsetinib, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Pemetrexed, BLU-667, N/A, Capsule, Concentrate for solution for infusion, Powder for solution for infusion, Lyophilisate for solution for infusion, Carboplatin, Cisplatin, Keytruda, Gemcitabine, Alimta
Blueprint Medicines Corporation, F. Hoffmann-La Roche Ltd, F. Hoffmann La-Roche Ltd, BLUEPRINT MEDICINES CORPORATION, Blueprint Medicines, F.Hoffmann-La Roche Ltd., F. Hoffmann La-Roche Ltd, F. Hoffmann-La Roche Ltd.
RET fusion-positive, Metastatic Non-Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/24
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous NSCLC

Checkmark From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
Checkmark From trial for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: From trial for NSCLC at ESMO 2020
Checkmark From trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC
More
Completed
3
334
RoW
Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed, Cisplatin or Carboplatin,Pemetrexed
BeiGene
Non-Small Cell Lung Cancer
10/20
04/23
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Checkmark Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Checkmark Full data presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2021
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
12/26
2019-003969-18: A study to evaluate Chemotherapy Plus Osimertinib against Chemotherapy Plus Placebo in patients with non-small cell lung cancer (NSCLC)

Not yet recruiting
3
204
Europe
Osimertinib 80 mg, Osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD9291, Film-coated tablet, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Non-Small Cell Lung Cancer, EGFRm locally adv or metastatic Non-Small Cell Lung Cancer., Diseases [C] - Cancer [C04]
 
 
CANOPY-1, NCT03631199 / 2018-001547-32: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Hourglass Oct 2021 - Dec 2021 : From CANOPY-1 trial in combination with Keytruda for 1L NSCLC
Checkmark PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Dec 2021 - Dec 2021: PFS data from CANOPY-1 trial in combination with pembrolizumab for 1L NSCLC
Checkmark P3 CANOPY-1 trial in combination with canakinumab
Dec 2018 - Dec 2018: P3 CANOPY-1 trial in combination with canakinumab
Active, not recruiting
3
673
Europe, Canada, Japan, US, RoW
canakinumab, ACZ885, canakinumab matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
08/21
06/27
CheckMate 816, NCT02998528 / 2016-003536-21: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Hourglass Oct 2023 - Oct 2023 : Additional results (Abstract #1261O) from CheckMate -816 trial of neoadjuvant Opdivo in combination with Yervoy in resectable NSCLC at ESMO 2023
Checkmark Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analyses from from CheckMate -816 trial in resectable NSCLC at ESMO 2022
Checkmark EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
Apr 2022 - Apr 2022: EFS data from the P3 CheckMate -816 trial in NSCLC at AACR 2022
More
Active, not recruiting
3
505
Europe, Canada, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Cisplatin, Vinorelbine, Gemcitabine, Docetaxel, Pemetrexed, Carboplatin, Paclitaxel, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non Small Cell Lung Cancer
09/21
11/28
2020-003562-39: Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Non-Small Cell Lung Cancer

Not yet recruiting
3
600
Europe
Zimberelimab, Domvanalimab, Carboplatin, Paclitaxel, Pemetrexed, AB122, AB154, Carboplatin, Paclitaxel, Pemetrexed, Concentrate for solution for infusion, Powder for concentrate for solution for infusion
Arcus Biosciences, Inc., Arcus Biosciences, Inc.
First Line Non-Small Cell Lung Cancer, First Line Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
2021-002193-63: A Phase 3 Study of Balstilimab Compared to Chemotherapy Chosen by the Investigator in Cervical Cancer.

Not yet recruiting
3
486
Europe
Balstilimab, pemetrexed, Gemcitabine, irinotecan, Topotecan, Vinorelbine, AGEN2034, Solution for injection, Concentrate for solution for infusion, Solution for infusion, Powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi, Gemcitabine, Irinotecan, Topotecan, Vinorelbine
Agenus, Inc., Agenus, Inc.
recurrent, persistent, or metastatic cervical cancer that have progressed after receiving platinum-based chemotherapy, Cancer that develops in a woman's cervix, Diseases [C] - Cancer [C04]
 
 
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Not yet recruiting
3
166
RoW
Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/21
10/23
JAVELIN Lung 100, NCT02576574 / 2015-001537-24: Avelumab in First-line NSCLC

Checkmark Data from JAVELIN Lung 100 trial for 1L NSCLC
Feb 2022 - Feb 2022: Data from JAVELIN Lung 100 trial for 1L NSCLC
Checkmark Avelumab program rollover study in solid tumor
Jan 2019 - Jan 2019: Avelumab program rollover study in solid tumor
Checkmark Registration study for 1L NSCLC
More
Completed
3
1214
Europe, Canada, Japan, US, RoW
Avelumab, Anti-PD-L1, MSB0010718C, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
First Line Non-Small Cell Lung Cancer
12/21
01/24
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Active, not recruiting
3
320
RoW
Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA
Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
06/22
12/23
2021-006374-24: A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung cancer Un ensayo clínico para comparar la eficacia de savolitinib más osimertinib frente a la quimioterapia para el tratamiento del cáncer de pulmón no microcítico

Not yet recruiting
3
324
Europe
Savolitinib, osimertinib 80 mg, osimertinib 40 mg, Cisplatin, Carboplatin, Pemetrexed, AZD6094, HMPL-504, AZD9291, Tablet, Film-coated tablet, Concentrate for solution for infusion, TAGRISSO
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico localmente avanzado o metastásico con mutación EGFR y MET positivo, Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
2021-005879-40: Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Estudio en fase III de patritumab deruxtecán frente a quimioterapia basada en platino en el CPNM metastásico o localmente avanzado con EGFRm tras el fracaso del tratamiento con ITC del EGFR

Not yet recruiting
3
560
Europe
Patritumab Deruxtecan, Pemetrexed, Cisplatin, Carboplatin, U3-1402, NA, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Vitamin B12 1000 µg, Folic Acid, Cisplatin, carboplatin, pemetrexed
Daiichi Sankyo, Inc., DAIICHI SANKYO INC., DAIICHI SANKYO. INC., Daiichi Sankyo, Inc.
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) metastásico o localmente avanzado con mutación del receptor del factor de crecimiento epidérmico (EGFRm), Non-small Cell Lung Cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM), Diseases [C] - Cancer [C04]
 
 
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Not yet recruiting
3
460
RoW
Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
10/22
10/23
PEARL, NCT03003962 / 2018-001375-21: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer

Checkmark Data from PEARL trial for Stage IV (metastatic) NSCLC
Dec 2022 - Dec 2022: Data from PEARL trial for Stage IV (metastatic) NSCLC
Checkmark From PEARL trial for 1L NSCLC
Oct 2021 - Oct 2021: From PEARL trial for 1L NSCLC
Active, not recruiting
3
669
Europe, US, RoW
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
10/22
06/26
AEGEAN, NCT03800134 / 2018-002997-29: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Event free survival data from AEGEAN trial for stage I and III resected NSCLC
Jan 2023 - Dec 2023: Regulatory submission for locally advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for advanced stage 3 NSCLC (based on AEGEAN trial)
Jan 2023 - Dec 2023: From AEGEAN trial for stage II and III resected NSCLC
More
Active, not recruiting
3
826
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
AstraZeneca
Non-Small Cell Lung Cancer
11/22
09/28
NCT04619433: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Recruiting
3
560
RoW
Camrelizumab;Pemetrexed and Carboplatin; Famitinib;, SHR1210, Camrelizumab;Pemetrexed and Carboplatin;Placebo
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous Non-small-cell Lung Cancer
12/22
10/23
KEYNOTE-789, NCT03515837 / 2017-004188-11: Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/)

Completed
3
492
Europe, Canada, Japan, US, RoW
pembrolizumab, MK-3475, pemetrexed, carboplatin, cisplatin, saline solution, Normal saline solution
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
01/23
10/23
IMpower151, NCT04194203: A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
3
305
RoW
Atezolizumab, Tecentriq, Placebo, Bevacizumab, Avastin, Paclitaxel, Pemetrexed, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
02/23
06/24
ORIENT-11, NCT03607539: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Checkmark Accepted for review for the treatment of Nonsquamous NSCLC
May 2021 - May 2021: Accepted for review for the treatment of Nonsquamous NSCLC
Checkmark Data from orient-11 trial with or without combination of pemetrexed plus platinum chemotherapy for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from orient-11 trial with or without combination of pemetrexed plus platinum chemotherapy for NSCLC at ESMO 2020
Checkmark From ORIENT-11 trial for advanced or metastatic NSCLC at ESMO 2020
More
Completed
3
397
RoW
Sintilimab, IBI308, Pemetrexed, Platinum, Placebos
Innovent Biologics (Suzhou) Co. Ltd.
Lung Neoplasms
02/23
02/23
FLAURA2, NCT04035486 / 2019-000650-61: A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - PDUFA date for FDA approval in adults with locally advanced/metastatic EGFRm NSCLC (based on FLAURA2 trial)
Jan 2022 - Dec 2023: Data from FLAURA2 trial in combination with carboplatin or pemetrexed/cisplatin for 1L EGFRm NSCLC
Active, not recruiting
3
587
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
AstraZeneca
Non-Small Cell Lung Cancer
04/23
06/26
KEYNOTE-A86, NCT04956692 / 2020-002729-27: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting
3
531
Europe, Japan, US, RoW
Pembrolizumab SC, Pembrolizumab IV, MK-3475, KEYTRUDA®, SCH 900475, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-Paclitaxel, Abraxane, Nanoparticle albumin-bound paclitaxel, Carboplatin, Paraplatin, Paraplatin NovaPlus, Cisplatin, Platinol-AQ, Pemetrexed, LY231514, Alimta, Pemetrexed Disodium
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Non-Small Cell Lung Cancer
04/23
10/26
ORIENT-31, NCT03802240: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Checkmark Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Checkmark Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Nov 2021 - Nov 2021: Interim analysis results of ORIENT-31 study of sintilimab plus Byvasda and chemo in EGFR-mutated nonsquamous NSCLC at ESMO Virtual Plenary 2021
Checkmark Data from first interim analysis in combination with Byvasda and chemo in EGFR mutated nonsquamous NSCLC
More
Completed
3
492
RoW
Sintilimab, IBI308, IBI305, Pemetrexed, Cisplatin, Placebo1, Placebo2
Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
07/21
06/23
LIBRETTO-431, NCT04194944 / 2019-001979-36: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
261
Europe, Canada, Japan, RoW
Selpercatinib, LY3527723, LOXO-292, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer
05/23
06/26
NCT06396065: Phase III Study of AK112 for NSCLC Patients

Recruiting
3
420
Europe, Canada, US
AK112 Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
12/25
12/25
NCT06212752: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Active, not recruiting
3
378
Japan
Pembrolizumab coformulated with hyaluronidase, MK-3475A, Pemetrexed, Alimta, Cisplatin, Platinol-AQ, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Pembrolizumab, MK-3475, KEYTRUDA, Filgrastim, Pegylated filgrastim
Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer
09/24
05/28
AK105-301, NCT03866980: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Terminated
3
164
RoW
AK105, carboplatin, pemetrexed, placebo, Anlotinib
Akeso, Akeso Tiancheng, Inc
Lung Cancer Non-small Cell Stage IV
06/23
12/23
MARIPOSA-2, NCT04988295: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Active, not recruiting
3
776
Europe, Canada, Japan, US, RoW
Lazertinib, JNJ-73841937, YH-25448, Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
07/23
12/25
2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio para comparar furmonertinib con quimioterapia basada en platino para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico

Not yet recruiting
3
375
Europe
Furmonertinib, AST2818, Tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion, Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Carboplatin Hikma 10 mg/mL concentrate for solution for infusion, Carboplatin Bendalis 10 mg/ml Concentrate for solution for infusion, Carboplatin Fresenius Kabi 10 mg/ml, concentrate for solution for infusion, Cisplatin Hikma 1mg/ml concentrate for solution for infusion, Cisplatin Accord 1 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml concentrate for solution for infusion
ArriVent BioPharma, Inc., ArriVent BioPharma, Inc., Shanghai Allist Pharmaceuticals Co., Ltd.
Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide sin tratamiento previo, localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico (RFCE), Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
568
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
LEAP-006, NCT03829319 / 2018-003824-35: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/)

Checkmark Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Sep 2020 - Sep 2020: Data from LEAP-006 trial in combination with pembrolizumab for NSCLC
Checkmark Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
Jul 2020 - Jul 2020: Data from LEAP-006 trial in combination with lenvatinib & platinum doublet chemo in mNSCLC at ESMO 2020
Checkmark Data from LEAP-006 trial in combination with pembrolizumab & platinum doublet chemo in mNSCLC at ESMO 2020
More
Active, not recruiting
3
761
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
LEAP-006 China Extension, NCT04716933: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

Active, not recruiting
3
201
RoW
Pembrolizumab, MK-3475, Carboplatin, Cisplatin, Pemetrexed, Lenvatinib, MK-7902, E7080, Placebo matching lenvatinib
Merck Sharp & Dohme LLC, Eisai Inc.
Nonsquamous Non-small Cell Lung Cancer
08/23
08/24
ORIENT-99, NCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Recruiting
3
500
RoW
Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin, Nab paclitaxel, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Non-Small Cell Lung Cancer
09/26
10/28
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
PACIFIC2, NCT03519971 / 2017-004397-34: Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Jul 2023 - Dec 2023: Acceptance of regulatory submission for CRT+ NSCLC (based on PACIFIC-2 trial)
Jul 2023 - Dec 2023: Data from PACIFIC-2 trial for advanced NSCLC
Hourglass Jan 2021 - Dec 2021 : Regulatory submission for advanced stage 3 NSCLC (based on PACIFIC-2 trial)
Active, not recruiting
3
328
Europe, Japan, RoW
Durvalumab, MEDI4736, Placebo, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin, Radiation
AstraZeneca
Non-Small Cell Lung Cancer
09/23
03/25
PAPILLON, NCT04538664 / 2020-000633-40: A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Active, not recruiting
3
308
Europe, Canada, Japan, US, RoW
Amivantamab, JNJ-61186372, Pemetrexed, Carboplatin
Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
05/23
01/26
NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
643
RoW
HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed
Shanghai Henlius Biotech
Carcinoma, Non-Small-Cell Lung
10/23
03/24
DOMAJOR, NCT03912389 / 2018-004791-36: Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

Recruiting
3
292
Europe, RoW
BCD-100, Pemetrexed, Cisplatin (or carboplatin), Placebo
Biocad
Non-Squamous Non-Small Cell Neoplasm of Lung
12/23
12/23
NCT05346952: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Recruiting
3
390
RoW
TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Non-squamous Non-small Cell Lung Cancer
12/23
12/23
CheckMate 77T, NCT04025879 / 2019-000262-38: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data readout CheckMate-77T trial for peri adjuvant NSCLC
Hourglass Nov 2023 - Mar 2024 : H2 FY’23 - Submission in Japan for neoadjuvant/adjuvant NSCLC based on CheckMate-77T trial
Active, not recruiting
3
482
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, BMS936558, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Placebo, Docetaxel
Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
07/23
09/24
Beamion LUNG-2, NCT06151574: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting
3
270
Europe, Japan, US, RoW
zongertinib, BI 1810631, pembrolizumab, Keytruda®, cisplatin, carboplatin, pemetrexed
Boehringer Ingelheim
Lung Cancer, Non-squamous, Non-small Cell
03/27
05/28
KEYNOTE-671, NCT03425643 / 2017-001832-21: Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/)

Calendar Jan 2024 - Dec 2024: From KEYNOTE-0671 trial for resectable stage IIb or IIIa NSCLC
Hourglass Sep 2019 - Oct 2019 : Preliminary data from trial for advanced solid tumors and genomic instability at ESMO 2019
Active, not recruiting
3
797
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Placebo, Cisplatin, PLATINOL®, Gemcitabine, GEMZAR®, Pemetrexed, Alimta®
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/23
06/26
BEAT-meso, NCT03762018 / 2018-002180-25: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Active, not recruiting
3
401
Europe
Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Pleural Mesothelioma Malignant Advanced
06/24
06/24
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
3
48
US
Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206
Maximilian Diehn, AstraZeneca
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
04/26
04/28
NCT06281964: Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Not yet recruiting
3
327
NA
PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab
Avistone Biotechnology Co., Ltd.
Non-Small-Cell Lung Cancer
01/26
12/26
MK-2870-019, NCT06312137: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR)

Recruiting
3
780
Europe, US, RoW
Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel
Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
02/34
10/34
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting
3
398
NA
JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC
03/27
03/28
EMPOWER-lung 1, NCT03088540 / 2016-004407-31: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Checkmark OS and PFS data for advanced or metastatic 1L NSCLC
Jul 2021 - Jul 2021: OS and PFS data for advanced or metastatic 1L NSCLC
Checkmark Approval in US for 1L NSCLC
Feb 2021 - Feb 2021: Approval in US for 1L NSCLC
Checkmark Data from study for advanced or metastatic PD L1+ve 1L NSCLC
More
Active, not recruiting
3
712
Europe, RoW
Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab, REGN2810, Libtayo
Regeneron Pharmaceuticals, Sanofi
Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer
06/25
06/25
ALINA, NCT03456076 / 2017-004331-37: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
257
Europe, Japan, US, RoW
Alectnib, RO5424802, Cisplatin, Vinorelbine, Navelbine, Gemcitabine, Gitrabin, Pemetrexed, Alimta®, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
06/23
11/26
BL-B01D1-301, NCT06382116: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
3
428
RoW
BL-B01D1, Pemetrexed+Cisplatin or Carboplatin
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/26
05/26
DREAM3R, NCT04181411: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Not yet recruiting
3
480
NA
Durvalumab, Imfinzi, MEDI4736, Cisplatin, Cisplatin injection, Pemetrexed, Alimta, Carboplatin, Carboplatin injection
University of Sydney, Australasian Lung Cancer Trials Group, PrECOG, LLC., AstraZeneca
Mesothelioma Malignant Advanced
06/24
06/24
MK-2870-009, NCT06305754: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Recruiting
3
520
US, RoW
Sacituzumab tirumotecan, SKB264, MK-2870, Pemetrexed, Carboplatin, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent)
Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
09/28
06/30
COMPEL, NCT04765059: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
98
Europe, US, RoW
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
AstraZeneca, Parexel
Non-small Cell Lung Cancer
12/24
12/24
NCT06452277: A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)

Not yet recruiting
3
278
Europe, Canada, Japan, US, RoW
BAY2927088, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Bayer
Advanced Non-small Cell Lung Cancer, HER2 Mutation
06/26
05/28
NeoADAURA, NCT04351555 / 2020-000058-89: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : Data from NeoADAURA trial for EGFRm NSCLC
Recruiting
3
328
Europe, Canada, Japan, US, RoW
Osimertinib, AZD9291; TAGRISSO, Cisplatin, Carboplatin, Placebo, Pemetrexed
AstraZeneca
Non-Small Cell Lung Cancer
07/24
06/29
POD1UM-304, NCT04205812 / 2019-003372-39: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Active, not recruiting
3
583
Europe, US, RoW
Retifanlimab, INCMGA00012, Placebo, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, nab-Paclitaxel
Incyte Corporation, Zai Lab (Shanghai) Co., Ltd.
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
12/23
04/25
QUILT2023, NCT03520686: QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Active, not recruiting
3
1538
US
N-803 + Pembrolizumab, N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab, N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, Pembrolizumab, Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab, Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed
ImmunityBio, Inc.
Non Small Cell Lung Cancer
10/25
04/26
NCT06459180: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Not yet recruiting
3
686
NA
Sacituzumab Tirumotecan, MK-2870, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Cervical Cancer
10/28
10/28
JAB-21822 3002, NCT06416410: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Not yet recruiting
3
392
NA
JAB-21822, Tislelizumab, JAB-3312, Pemetrexed, Carboplatin
Jacobio Pharmaceuticals Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
09/26
02/27
BGB-A317-290-LTE1, NCT04164199 / 2019-002554-23: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation
3
300
RoW
Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
BeiGene
Advanced Malignancies
12/26
12/26
NCT06430437: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Not yet recruiting
3
300
RoW
SHR-A1811, Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer With HER2- Mutations
02/26
04/27
TROPION Lung15, NCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruiting
3
630
NA
Dato-DXd, DS-1062a, Osimertinib, Tagrisso, AZD9291, Pemetrexed, Carboplatin, Cisplatin
AstraZeneca, Daiichi Sankyo
Metastatic Non-small Cell Lung Cancer
09/26
02/28
KEYLYNK-006, NCT03976323 / 2018-004720-11: Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, )

Calendar Jul 2024 - Sep 2024: From KEYLYNK-006 trial +/- Lynparza for 1L metastatic non squamous NSCLC
Active, not recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, PLATINOL®-AQ, Olaparib, LYNPARZA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Carcinoma, Non-squamous Non-small-cell Lung
02/24
01/25
NCT06280196: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Not yet recruiting
3
676
NA
BAT3306, Pembrolizumab Injection, EU-Keytruda®, US-Keytruda®, Pemetrexed, Pemetrexed Fresenius Kabi, Carboplatin, Carboplatin Kabi
Bio-Thera Solutions
Carcinoma, Non-Small-Cell Lung
07/27
10/28
CheckMate 227, NCT02477826 / 2014-003630-23: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Checkmark Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Yervoy for 1L NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 227 trial in combination with Opdivo for 1L NSCLC at ASCO 2022
Checkmark From CheckMate 227 trial in combination with Yervoy for NSCLC at ASCO 2021
More
Active, not recruiting
3
2748
Europe, Canada, Japan, US, RoW
Nivolumab, Opdivo, Ipilimumab, Yervoy, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Non-Small Cell Lung Cancer
08/24
08/24
IMpower010, NCT02486718 / 2014-003205-15: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer []

Checkmark Data from IMpower010 trial for stage IB-IIIA NSCLC
Aug 2022 - Aug 2022: Data from IMpower010 trial for stage IB-IIIA NSCLC
Checkmark Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Aug 2022 - Aug 2022: Results from IMpower010 trial in for adjuvant NSCLC at IASLC-WCLC
Checkmark Approval for adjuvant NSCLC based on IMpower010
More
Active, not recruiting
3
1280
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A; TECENTRIQ, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
Hoffmann-La Roche
Non-Small Cell Lung Cancer
01/24
08/35
NCT04736173: Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2026: Data from ARC-10 trial for 1L PD-L1 NSCLC
Active, not recruiting
3
169
Europe, US, RoW
Domvanalimab, AB154, Zimberelimab, AB122, Carboplatin, Paclitaxel, Pemetrexed, Pembrolizumab
Arcus Biosciences, Inc., Gilead Sciences
Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
08/24
07/27
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Recruiting
3
250
RoW
Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin
Hutchison Medipharma Limited
Non-small Cell Lung Cancer
09/24
11/24
MK-3475A-D77, NCT05722015: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
378
Europe, Japan, US, RoW
Pembrolizumab coformulated with hyaluronidase, MK-3475A, Pemetrexed, Alimta, Cisplatin, Platinol-AQ, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Pembrolizumab, MK-3475, KEYTRUDA, Filgrastim, Pegylated filgrastim
Merck Sharp & Dohme LLC
Metastatic Non-small Cell Lung Cancer
09/24
05/28
AcceleRET Lung, NCT04222972: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
223
Europe, Japan, US, RoW
Pralsetinib, BLU-667, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab, Gemcitabine, Paclitaxel, Nab-Paclitaxel
Hoffmann-La Roche
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Diseases, Head and Neck Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue
06/25
06/25
NCT05132413: A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Not yet recruiting
3
561
NA
SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab, Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin, Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
12/24
12/24
HS-10241-301, NCT06110663: A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Not yet recruiting
3
314
NA
HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
12/24
02/25
HARMONi, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Recruiting
3
470
Europe, Canada, US, RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Summit Therapeutics, Akeso
Non-Squamous Non-small Cell Lung Cancer
01/25
01/26
DESTINY-Lung04, NCT05048797 / 2021-000634-33: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for advanced NSCLC (based on DESTINY-Lung04 trial)
Calendar Jan 2024 - Dec 2024: Data from DESTINY-Lung04 trial for locally advanced/metastatic NSCLC
Checkmark Initiated DESTINY-Lung04 trial in HER2 exon 19/20 gene mutation-positive advanced or metastatic NSCLC
Oct 2021 - Oct 2021: Initiated DESTINY-Lung04 trial in HER2 exon 19/20 gene mutation-positive advanced or metastatic NSCLC
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Trastuzumab Deruxtecan, DS-8201a; T-DXd, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed
AstraZeneca, Daiichi Sankyo
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
06/25
03/27
IMpower030, NCT03456063 / 2017-002857-12: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Data from IMpower030 trial for neoadjuvant NSCLC
Hourglass Jan 2022 - Dec 2022 : EFS data from P3 IMpower030 trial for resectable stage II, IIIA, or select IIIB NSCLC
Active, not recruiting
3
453
Europe, Japan, US, RoW
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Tecentriq, Placebo Comparator, Nab-paclitaxel, Abraxane, Pemetrexed, Alimta, Carboplatin, Cisplatin, Gemcitabine, Gemzar
Hoffmann-La Roche
Non-Small-Cell Lung
01/25
01/25
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
04/25
12/25
SKB264-Ⅲ-09, NCT05870319: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Recruiting
3
356
RoW
SKB264, Pemetrexed, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/25
09/26
SAFFRON, NCT05261399: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Recruiting
3
324
Europe, Canada, Japan, US, RoW
Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
06/25
12/26
RATIONALE-315, NCT04379635: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
453
RoW
Tislelizumab, BGB-A317, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin
BeiGene
Non Small Cell Lung Cancer
06/25
11/25
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not yet recruiting
3
642
RoW
AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel
Akeso
Locally Advanced or Metastatic NSCLC
08/25
11/26
MRG002-010, NCT05754853: A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting
3
290
RoW
MRG002, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium Injection
Shanghai Miracogen Inc.
Advanced or Metastatic Urothelium Cancer
10/25
01/27
KEYVIBE 007, NCT05226598 / 2021-004564-94: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Active, not recruiting
3
700
Europe, Japan, US, RoW
Pembrolizumab/Vibostolimab, MK-7684A, Carboplatin, PARAPLATIN®, Paraplatin NovaPlus ®, Cisplatin, Platinol-AQ®, Paclitaxel, TAXOL®, ONXOL®, Nab-paclitaxel, ABRAXANE®, Pemetrexed, Alimta®, Pembrolizumab, MK-3475, KEYTRUDA®
Merck Sharp & Dohme LLC
Metastatic Non-Small Cell Lung Cancer
06/26
09/27
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
62
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
NCT05112965: An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Recruiting
3
100
RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Pemetrexed, Paclitaxel, Enzalutamide, Xtandi
Hoffmann-La Roche
Neoplasms
12/25
12/25
EXCLAIM-2, NCT04129502 / 2019-001845-42: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Active, not recruiting
3
354
Europe, Canada, Japan, US, RoW
TAK-788, AP32788, Mobocertinib, Pemetrexed, Alimta, Cisplatin, Carboplatin
Takeda
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
12/24
12/24
 

Download Options